Danaher (NYSE:DHR) Sets New 1-Year High at $269.11

Shares of Danaher Co. (NYSE:DHRGet Free Report) reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $269.11 and last traded at $267.94, with a volume of 2007611 shares. The stock had previously closed at $267.85.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on DHR shares. HSBC upgraded Danaher from a “hold” rating to a “buy” rating and boosted their price target for the company from $250.00 to $280.00 in a report on Wednesday, April 17th. Barclays upped their price target on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 24th. TD Cowen lifted their price objective on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Bank of America boosted their price objective on shares of Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 24th. Finally, Citigroup raised their target price on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Six equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $269.29.

Check Out Our Latest Research Report on Danaher

Danaher Price Performance

The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. The business has a fifty day moving average of $251.96 and a 200 day moving average of $242.75. The firm has a market cap of $194.76 billion, a P/E ratio of 44.57, a PEG ratio of 4.10 and a beta of 0.85.

Danaher (NYSE:DHRGet Free Report) last issued its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. During the same period in the previous year, the company posted $2.36 EPS. The firm’s revenue for the quarter was down 2.6% compared to the same quarter last year. On average, sell-side analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.41%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s dividend payout ratio is presently 18.31%.

Insider Buying and Selling

In related news, SVP Brian W. Ellis sold 4,000 shares of Danaher stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total transaction of $1,000,040.00. Following the completion of the sale, the senior vice president now directly owns 29,830 shares of the company’s stock, valued at approximately $7,457,798.30. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CEO Rainer Blair sold 47,175 shares of the firm’s stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the transaction, the chief executive officer now directly owns 115,995 shares of the company’s stock, valued at $28,908,273.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Brian W. Ellis sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total value of $1,000,040.00. Following the completion of the sale, the senior vice president now owns 29,830 shares of the company’s stock, valued at $7,457,798.30. The disclosure for this sale can be found here. In the last 90 days, insiders sold 148,783 shares of company stock valued at $37,536,717. Company insiders own 11.10% of the company’s stock.

Hedge Funds Weigh In On Danaher

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DHR. DekaBank Deutsche Girozentrale increased its position in shares of Danaher by 4.3% in the first quarter. DekaBank Deutsche Girozentrale now owns 710,636 shares of the conglomerate’s stock worth $176,325,000 after purchasing an additional 29,081 shares during the period. Cambridge Trust Co. increased its holdings in Danaher by 17.5% in the 1st quarter. Cambridge Trust Co. now owns 87,500 shares of the conglomerate’s stock valued at $21,850,000 after buying an additional 13,062 shares during the period. Soltis Investment Advisors LLC acquired a new position in shares of Danaher in the 1st quarter valued at approximately $290,000. Cetera Advisor Networks LLC lifted its holdings in shares of Danaher by 6.3% during the 1st quarter. Cetera Advisor Networks LLC now owns 72,454 shares of the conglomerate’s stock worth $18,093,000 after acquiring an additional 4,266 shares during the period. Finally, Cetera Advisors LLC boosted its position in shares of Danaher by 44.3% during the 1st quarter. Cetera Advisors LLC now owns 27,346 shares of the conglomerate’s stock worth $6,829,000 after acquiring an additional 8,389 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Company Profile

(Get Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Featured Articles

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.